The following is a list of major therapeutic classes with drugs that are substantially metabolized by CYP3A.
Statins: atorvastatin, simvastatin, lovastatin.
Calcium channel blockers: nifedipine, verapamil, nicardipine, felodipine, nisoldipine.
Antiplatelets: clopidogrel, prasugrel, ticagrelor, cilostazol.
Antiarrhythmics: amiodarone, quinidine, disopyramide, lidocaine.
Example of angina treatments: ranolazine.
Angiotensin II Inhibitors: losartan.
Anticoagulants: rivaroxaban, apixaban.
The following is a list of major inhibitors that compete with other drugs for a particular enzyme thus affecting the optimal level of metabolism of the substrate drug which in many cases affect the individual's response to that particular medication, e.g. making it ineffective.
A Strong inhibitor is one that causes a > 5-fold increase in the plasma AUC values or more than 80% decrease in clearance. This include: indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole,nefazodone, saquinavir, telithromycin
A Moderate inhibitor is one that causes a > 2-fold increase in the plasma AUC values or 50-80% decrease in clearance. This include: aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil, diltiazem
A Weak inhibitor is one that causes a > 1.25-fold but < 2-fold increase in the plasma AUC values or 20-50% decrease in clearance such as cimetidine, amiodarone, chloramphenicol, boceprevir, ciprofloxacin, delaviridine, diethyl, dithiocarbamate, fluvoxamine, gestodene, imatinib, mibefradil, mifepristone, norfloxacin, norfluoxetine, starfruit, telaprevir, voriconazole